



HAL
open science

Insights on animal models to investigate inhalation therapy: Relevance for biotherapeutics

A. Guillon, Thomas Secher, L.A. Dailey, L. Vecellio, M. de Monte, Mustapha Si-Tahar, P. Diot, C.P. Page, N. Heuzé-Vourc'H

► To cite this version:

A. Guillon, Thomas Secher, L.A. Dailey, L. Vecellio, M. de Monte, et al.. Insights on animal models to investigate inhalation therapy: Relevance for biotherapeutics. *International Journal of Pharmaceutics*, 2018, 536 (1), pp.116-126. 10.1016/j.ijpharm.2017.11.049 . hal-02439838

HAL Id: hal-02439838

<https://hal.science/hal-02439838>

Submitted on 3 Jun 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Insights on animal models to investigate inhalation therapy: relevance for biotherapeutics**

2

3 Guillon A^{1,2,3}, Sécher T^{1,2}, Dailey LA⁴, Vecellio L^{1,5}, De Monte M⁶, Si-Tahar M^{1,2}, Diot P^{1,2,7}, Page CP⁸, Heuzé-
4 Vourc'h N^{1,2}

5

6 1. INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, F-37032 Tours, France

7 2. Université François Rabelais de Tours, F-37032 Tours, France

8 3. CHRU de Tours, Service de Réanimation Polyvalente, F-37000 Tours, France

9 4. Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06122
10 Halle (Saale), Germany

11 5. Aerodrug, Université François Rabelais - Faculté de Médecine, Tours, France

12 6. Plateforme Scientifique et Technique (PST) Animaleries, Université F. Rabelais, F-37000 Tours, France

13 7. CHRU de Tours, Service de Pneumologie, F-37000 Tours, France

14 8. Sackler Institute of Pulmonary Pharmacology and Institute of Pharmaceutical Science, King's College
15 London, 150 Stamford Street, London SE1 9NH, UK

16

17

18 **Corresponding Author:**

19 Dr Heuzé-Vourc'h Nathalie

20 INSERM, Centre d'Etude des Pathologies Respiratoires, U1100

21 Université François Rabelais de Tours

22 10 Boulevard Tonnellé

23 F-37032 Tours, France

24 nathalie.vourch@med.univ-tours.fr

25 Tel : (0033)247366237; fax : +33 2 47 36 60 46

26

27

28 **Abstract**

29

30 Acute and chronic respiratory diseases account for major causes of illness and deaths worldwide.
31 Recent developments of biotherapeutics opened a new era in the treatment and management of patients with
32 respiratory diseases. When considering the delivery of therapeutics, the inhaled route offers great promises with
33 a direct, non-invasive access to the diseased organ and has already proven efficient for several molecules. To
34 assist in the future development of inhaled biotherapeutics, experimental models are crucial to assess lung
35 deposition, pharmacokinetics, pharmacodynamics and safety. This review describes the animal models used in
36 pulmonary research for aerosol drug delivery, highlighting their advantages and limitations for inhaled
37 biologics. Overall, non-clinical species must be selected with relevant scientific arguments while taking into
38 account their complexities and interspecies differences, to help in the development of inhaled medicines and
39 ensure their successful transposition in the clinics.

40

41

42 **Keywords:** Animal models; Inhalation therapy; Biotherapeutics

43

44 1. Introduction

45

46 Over the last decades, the respiratory drug pipeline has broadened to include a large array of
47 biotherapeutics which have ushered in a new chapter in the management and treatment of patients with
48 respiratory diseases (Reichert, 2016). As an example, in the past two years two monoclonal antibodies
49 (mepolizumab and reslizumab) received approval for severe asthma, providing further options for the treatment
50 of severe asthma. When considering the administration of large drug molecules, like biotherapeutics, matching
51 the delivery route to the relevant anatomical location is paramount (Desoubieux et al., 2016). The delivery of
52 drugs for treating respiratory diseases by inhalation has long been considered to allow a rapid onset of action, to
53 ensure a high concentration of drugs in the vicinity of the relevant anatomical region while limiting systemic
54 exposure and reducing the likelihood of side-effects. Inhalation is commonly used for small molecule drugs to
55 improve their therapeutic index, but appears more complicated for biotherapeutics, with only one protein,
56 Dornase alpha (Pulmozyme™), approved for the treatment of cystic fibrosis by inhalation (Dentice and Elkins,
57 2016), and few additional inhaled biotherapeutics in clinical evaluation (alpha anti-trypsin, an anti-RSV
58 nanobody™ and two monoclonal antibody (mAb) fragments). Indeed, inhalation of biotherapeutics raises
59 technical and formulation challenges (e.g. stability during aerosolization), pharmacological issues related to
60 their fate and action after pulmonary deposition, and safety issues (Respaud et al., 2015). To improve the
61 development of inhaled biotherapeutics and avoid failure to translate promising drugs from animal models to
62 humans, it is crucial to use/develop more predictive preclinical models. For the development of inhaled drugs,
63 local lung tolerance is one of the most critical aspects and requires the use of several animal species. On the
64 other hand, assessing *in vivo* lung deposition, pulmonary pharmacokinetics (PK) and pharmacodynamics (PD)
65 are also essential to understand the fate and specific effects of inhaled liquid or solid (powder) formulations.
66 Given the variability of the deposition of inhaled particles in the airways, as well as their clearance and
67 pharmacological effects, a large number of animal species have been used in preclinical studies. Rodents (rats
68 and mice) are the most commonly used species, but larger mammals such as dogs and primates are often
69 required for toxicological evaluation. Although animals are necessary, they all display their own limitations as
70 models of humans. Thus, when considering non-clinical studies of inhaled materials in experimental mammals it
71 is imperative to take into consideration the anatomy of the airways, the characteristics of particle deposition and
72 clearance, as well as methods of exposure (inhalation chambers, masks, etc...), and the practical design of the
73 experimental protocol. Other factors are also important, such as biotherapeutic interaction with the molecular
74 target and animal host system, ease of handling animal models, and technical constraints linked to animal
75 housing and/or the availability of specific techniques. This review describes existing approaches to the use of
76 experimental animals regarding aerosol drug deposition, PK/PD and toxicity, and discusses the limitations of
77 these models with respect to the anatomical and physiological characteristics of the respiratory system.

78

79

80 2. Animal models and aerosol delivery

81

82 Studies dealing with modelling and/or comparison of deposition of inhaled particles by the most
83 common laboratory species are based on a limited amount of data (Derelanko and Hollinger, 1995; McClellan
84 and Henderson, 1989; Schlesinger, 1985). It is likely that total deposition of an inhaled aerosol might be similar
85 in mammals with equal mass, despite distinct anatomical features, whereas there might be greater inter-species
86 variations in terms of regional deposition (Phalen et al., 2008). Overall, anatomical characteristics of the lungs
87 and respiratory parameters differ considerably among mammals and clearly matter when evaluating aerosol
88 deposition and for translating results from animal models to humans.

89

90 2.1 Rationale for species selection

91

92 Many species are suitable for studies of aerosol deposition of drugs in the lungs, but a rigorous
93 comparative analysis of the airway anatomy and physiology is mandatory in the selection of an animal model in
94 order to extrapolate the results to humans. The structure of the respiratory apparatus changes significantly across
95 species with regard to the anatomy of the nose, the overall anatomy of the lung, the tracheobronchial tree, and
96 the lower lung. Interspecies comparisons of breathing parameters have been reviewed in more detail elsewhere
97 (Cryan et al., 2007) and key differences in individual anatomical, biological and physiological parameters are
98 discussed below.

99

100 2.1.1 Comparative anatomy of the lung, from the nose to the alveoli

101 Small laboratory rodents are unable to breathe through the mouth, breathing only through the nose,
102 similar to humans during the neonatal period. In contrast, most other mammals preferentially breathe through
103 the nose, although they are also able to breathe through the mouth, as do pigs in hyperventilation or non-human
104 primate (NHP) with nasal obstruction. The nose in humans and other primates consists of several superimposed
105 shelf-like structures (turbinates) projecting into the nasal cavities with a small olfactory region. The turbinates
106 cause turbulence of the inhaled air. In contrast, the nasal anatomy of most other mammals is more complex, with
107 double-scrolled turbinates and large olfactory regions (Schneider and Raabe, 1981). Anatomical comparison can
108 be misleading because the nasal cavity is not uniformly ventilated. Only 10-15% of the inspired air-stream
109 follows a dorsal pathway of the rat nose and flows over the complex ethmoturbinate. Thus, whereas the
110 ethmoturbinate structure in the rat is quite different than in the human, little of the inspire air passes through this
111 region (Salem and Katz, 2005). Magnetic resonance imaging (MRI) studies have shown that there are many
112 similarities in the structure of the monkey and human nose suggesting that the rhesus monkey is a good human
113 surrogate in aerosol deposition studies (Yeh et al., 1997). In contrast to humans, nose-breathing rodents exhibit a
114 lower pulmonary deposition accompanied by a higher nasal and tracheobronchial deposition, when inhaling
115 large particles (> several μm) (Schlesinger, 1985). When comparing pulmonary aerosol deposition of large
116 particles, in conditions of nasal breathing between humans and other species, deposition is similar in humans
117 and NHP, but greater in humans than in rats (Phalen et al., 2008). Interestingly, adapting the aerosol device to
118 minimize large particles may reduce the nasal particle trapping, as demonstrated in guinea pigs (Wu et al.,
119 2011).

120 Some of the main anatomical features of the respiratory tract of laboratory species are compared to
121 those of humans in Figure 1. The size of the thoracic cavity varies according to the species, which consequently
122 affects the size and volume of the lungs. The overall shape of the airway is of particular significance, as seen in
123 the relatively dichotomous and symmetrical branching scheme of the tracheobronchial system of primates as
124 compared to the long tapering monopodial airways of small rodents. These anatomical variations may introduce
125 changes in direction of the airflow favoring aerosol impaction and thus alteration in deposition pattern (Warheit,
126 1989). Such particular impaction “hotspots” at bifurcations in the human tracheobronchial tree have been
127 described in detail elsewhere (Balashazy et al., 2003). In species with monopodial branching patterns, and more
128 particularly in the rat, the particles carried in the airflow continue into the major daughter airways with little
129 change in velocity or direction, with deposition occurring largely by sedimentation (Warheit, 1989). Rodents
130 also differ from humans and NHPs in that they have no respiratory bronchioles. In the rat, the terminal
131 bronchioles, the smallest conductive part of the respiratory tract, are connected directly into the alveolar ducts
132 (Phalen and Oldham, 1983; Tyler, 1983). Mammals are also distinguished by the number and size of the
133 pulmonary acini. The size and number of alveoli and the lung area increase with the size of the animal
134 (Derelanko and Hollinger, 1995). Lobulation of the lung is more or less pronounced among species. The left
135 lung is generally divided into two lobes (e.g. humans, pigs, rabbits, guinea-pigs) or three (e.g. rhesus or
136 cynomolgus monkeys) and the right lung into three. The left lung remains single-lobed in certain rodents such as
137 the rat and the mouse, while the right lung is divided into four lobes.

138

139 *2.1.2 Impact of specific physiological and biological characteristics on aerosol administration*

140 In addition to inter-species anatomical differences, there are considerable inter-species physiological
141 and biological differences in lungs that may impact relevance of animal studies to predict aerosol deposition in
142 humans. First, there are significant differences in the lung volumes and breathing pattern across different
143 species. As summarized in Figure 2, the tidal volume increases with body weight, but in contrast, the respiratory
144 rate drastically decreases with an increase in body weight. Thus, extrapolation of results from lung deposition
145 studies in mice to humans is challenging. Second, the rate of inhaled particle absorption is not homogenous
146 across species. Absorption of lipid-insoluble drugs varies importantly according to species, whereas lipid-
147 soluble drugs are equally absorbed into the bloodstream of various animal species and are poorly affected by
148 clearance mechanisms (Phalen et al., 2008; Schanker et al., 1986). Moreover, non-clinical studies are often
149 carried out in animals at an early stage of life while the rates of lung absorption vary according to age (Schanker
150 and Hemberger, 1983).

151 Complex mechanisms of non-absorptive clearance following lung deposition can also modify the
152 bioavailability of drugs in the lung, such as mucociliary clearance, protease digestion and/or phagocytosis.
153 Indeed, morphometric investigations in rats, dogs, baboons, and humans revealed variations in the distribution
154 of alveolar macrophages (Crapo et al., 1983). Human lungs contained significantly greater number of alveolar
155 macrophages which may have implications for non-absorptive clearance (Crapo et al., 1983). Inhaled particles
156 are cleared from the tracheobronchial region by the ciliary action of the epithelial cells lining the airways, the so
157 called “mucociliary escalator”. The speed of tracheobronchial clearance is difficult to compare between species
158 since the size and length of the tracheobronchial tree are highly heterogeneous. Furthermore, small rodents
159 (mice, rabbit) lack bronchial submucosal glands (March et al., 2000). Finally, distribution of the

160 pharmacological effectors/modulators may be distributed differently within the lungs in animal species and limit
161 result translation to human. As an example, the neonatal Fc receptor (FcRn), known for its role in IgG
162 homeostasis, is a critical factor in the biodistribution and PK of mAbs and is differently expressed across species
163 (Roopenian and Akilesh, 2007). FcRn is expressed by numerous cell types such as epithelial cells, endothelial
164 cells, and macrophage/monocytes, in which it prevents IgG degradation in the lysosomes and contributes to IgG
165 recycling and transcytosis. While FcRn is expressed by the alveolar macrophages of all species, there are
166 differences in the sites of FcRn expression in the respiratory epithelium. FcRn expression is restricted to the
167 epithelial cells of the upper airways in primates, whereas it is also detected in the epithelium of the alveolar
168 region in rodents.

169

170 2.2 Methods of aerosol administration

171

172 2.2.1 Non-invasive aerosol delivery in spontaneously breathing animals

173 *Whole-body inhalation.* Whole-body inhalation systems are particularly convenient for inhalation
174 studies using large numbers of animals. Another advantage of whole-body inhalation systems is the ability to
175 expose conscious animals without restraint, thereby limiting experimental artefacts. However, a large proportion
176 of the aerosol is deposited on the animal's fur, with low lung deposition (<10% of the administered dose) and
177 confounding PK results due to intestinal absorption. For biotherapeutics such as mAbs, protein degradation in
178 the stomach is probably associated with a low transfer of the intact drug in the bloodstream. Thus, one would
179 assume that the gastrointestinal-tract absorption may poorly interfere with PK of inhaled biotherapeutic drugs.
180 In addition, the size of inhaled particles cannot be controlled, and the exact quantity of drug administered to the
181 lung is difficult to determine (Kawajiri et al., 2004; March et al., 2004; Pauluhn, 2006). Furthermore, this
182 system is not recommended for expensive drugs, like biotherapeutics, because of important drug loss. Another
183 confounding factor is coming from the fact that animals are in a horizontal position (standing on four legs)
184 during aerosol delivery, which favors ventral lung deposition. For these reasons, whole-body inhalation systems
185 are rather used to simulate airborne virus infection (Belser et al., 2015) or cigarette smoke exposure (Guillon et
186 al., 2015b).

187 *Nose-only inhalation.* Nose-only inhalation systems are generally preferred to reduce absorption by
188 non-respiratory routes. This system also affords measurement of respiratory parameters by plethysmography
189 during exposure, thereby allowing variability in dosing due to differences in individual animal breathing
190 patterns to be addressed (Pauluhn and Mohr, 2000). Nonetheless, a large amount of aerosol is still deposited in
191 the nasal cavity, due to nasal breathing of experimental animals. This fraction may be transferred to the
192 gastrointestinal compartment following mucociliary clearance where it can be absorbed into the bloodstream.
193 This may impact the interpretation of the results of PK or toxicity studies. As previously mentioned
194 gastrointestinal absorption may poorly interfere with PK of protein therapeutics. In contrast, biotherapeutic
195 deposition in the nose and further direct adsorption may biased PK analysis. Indeed, recent data supports
196 expression of FcRn in the nasal epithelium and its role in antibody/IgG transcytosis through the nasal epithelium
197 (Heidl et al., 2016).

198 *Face-mask inhalation.* Large mammals can breathe spontaneously through a face mask connected to an
199 aerosol generator (Supplementary figure 1) (Marchand et al., 2015). However, because the facial features of the

200 animal differ from those of a human, a mask interface is necessary to connect human devices, such as pediatric
201 aerosol generators, nebulizers or pMDIs with inhalation chambers. Although, a quantity of aerosol is lost in the
202 device and the mask interface, a significant quantity of the aerosol is deposited in the respiratory tract.
203 Interestingly, face-mask inhalation in macaque has been recently used for the preclinical development of a drug
204 and device system envisioned for the delivery of a mAb into the deep lungs of adults. As expected, mAb
205 deposition in the lungs of macaque was lower than the dose predicted by cascade impaction, because macaque
206 have ventilation parameter comparable to infants (Respaud et al., 2016).
207 Other limitations include the requirement of animal training prior to aerosol administration and the use of
208 anesthetics that can affect breathing parameters (Iizuka et al., 2010). Despite the limited relevance of these
209 methods to evaluate the relationship between the effectiveness/toxicity and the dose administered, and the
210 difficulties to accurately predict lung deposition, these methods are used and validated for lung tolerance and
211 regulatory toxicity studies. Like for other methods described above, gastrointestinal deposition is important by
212 face-mask inhalation - probably consecutive to direct swallowing or licking and subsequent swallowing of the
213 drugs deposited in the mouth and/or on the face – but may have a limited impact on protein therapeutic
214 pharmacology (Respaud et al., 2016). For example, face-mask inhalation has been used during the preclinical
215 development of ALX-0171, an anti-RSV nanobody™, to assess PK and anti-viral effects in a neonatal lamb
216 RSV infection model (Larios Mora et al., 2015). It is also worth noting that these methods could be particularly
217 useful to study lung tolerance following repeated drug exposure (Pauluhn, 2014).

218

219 2.2.2 *Intra-tracheal aerosol delivery*

220 *Intra-tracheal delivery in small rodents.* To bypass the oro-pharynx during administration and ensure a
221 full dose delivery in the lung, intra-tracheal instillation has been widely described in anesthetized animals using
222 either the Saffioti's method (Saffioti et al., 1968) or alternatively following tracheotomy or orotracheal
223 intubation. To overcome issues associated with intra-tracheal instillation, a large number of devices allowing the
224 delivery of a spray/aerosol directly into the trachea of rodents have been developed (Chen et al., 2002;
225 Hamacher et al., 2008; Rivera et al., 2005; Spoelstra et al., 2007; Todo et al., 2003). Intra-tracheal
226 administration in rodents using spray/aerosol devices, such as the MicroSprayer® Aerosolizer and Dry Powder
227 Insufflator™ (Penn-Century Inc., US), allows the rapid and reliable delivery of a controlled quantity of drug
228 directly into the lungs (Supplementary figure 2) (F. Gagnadoux et al., 2005; Mercier et al., 2014). These devices
229 can be used with liquid or solid drugs (e.g. anti-cancer agents and anti-fungals) or excipients at single or
230 repeated doses, to assess efficacy, tolerance and PK (Chandenier et al., 2009; Frédéric Gagnadoux et al., 2005;
231 Gagnadoux et al., 2008; Maillet et al., 2011; Montharu et al., 2010). The Microsprayer™ device has been used
232 with success to assess the efficacy of several mAbs in murine models (Guilleminault et al., 2014; Hervé et al.,
233 2014; Maillet et al., 2011). It should be noted however that tolerability issues have been raised concerning intra-
234 tracheal administration with these devices in small rodents (slight and transitory lung inflammation (Dubois et
235 al., 2013; Montharu et al., 2010) and lung lesions (Guillon et al., 2012)). A nebulization catheter device
236 (AeroProbe™, Trudell Medical International, Canada) was also commercialized to administer aerosols directly
237 into the airways and to provide a complementary approach to existing methodologies for pulmonary drug
238 delivery in small animals (Tronde et al., 2002). However, to the best of our knowledge, these devices are no
239 longer commercially available. Aerosol delivery systems for tracheal intubated and mechanically ventilated

240 mice have also been described (Robichaud et al., 2015). These nebulizers are integrated into the inspiratory
241 branch of the ventilator; however, laboratory-related protocol variations greatly affect the efficiency of the
242 aerosol generation process and avoid study comparisons (Robichaud et al., 2015).

243 In certain experimental scenarios (e.g. when a very mild anesthesia is necessary), alternative
244 administration techniques, such as oropharyngeal aspiration or intranasal administration may be used.
245 Oropharyngeal aspiration is limited to the administration of liquid solutions or suspensions to the lungs, as it
246 involves applying a small droplet (typically 25 to 50 μL per mouse) at the top of the pharynx and allowing the
247 droplet to be aspirated into the lungs during normal inhalation (Foster et al., 2001; Lakatos et al., 2006; Rao et
248 al., 2003). Although, this dosing technique is primarily used in the generation of murine disease models (such as
249 chemically induced asthma (De Vooght et al., 2009; Morgan et al., 2008) or bleomycin-induced lung fibrosis
250 (Babin et al., 2012)), it was used with success to deliver biotherapeutics (Respaud et al., 2016). It was also
251 demonstrated that oropharyngeal aspiration generated similar lung deposition profiles as MicroSprayer®
252 Aerosolizer instillation, notwithstanding a quicker overall process and the requirement for milder anaesthetic
253 regimes (Patel et al., 2016; Woods et al., 2015). However, this method may induce a bias in PK studies due to
254 intestinal absorption. Overall, commercial intra-tracheal administration devices, unlike traditional aerosol
255 administration devices (inhalation chambers), allow the dose of the product to be controlled, ensuring a high
256 deposition rate (70 to 80% of delivered dose) and a relatively uniform distribution of the product in the lungs of
257 larger rodents, such as rats. They also allow rapid and repeated administrations of the drug into the lungs, which
258 is suited to evaluate the efficacy of inhaled biotherapeutics. Finally, one has to consider that intra-tracheal
259 aerosol delivery in obligate nasal breathers is not exempted of drug deposition in the nasal cavity. Indeed, a part
260 of the aerosol still floats and remains in upper airway after the aerosol delivery. When the animal exhaled
261 through the nose, the aerosol could also be transported on the walls of nasopharynx (Yamamoto et al., 2017).

262 *Intra-tracheal delivery in large mammals.* Intra-tracheal administration in intubated large animals is
263 particularly relevant to mimic aerosol delivery during invasive mechanical ventilation in humans. Primates can
264 be intubated and mechanically ventilated using respiratory parameters mimicking “pediatric patients”. Pigs are
265 commonly used as a model for aerosol administration to ventilated patients in intensive care units (Rouby et al.,
266 2012). In these models, human devices can be used without any modifications and synchronized to inspiratory
267 time if needed. Despite their tracheal bronchus and the difficulty of oro-tracheal intubation due to their long
268 mouth cavity and curved larynx, the lung anatomy and physiology of pigs are close to that of humans, which
269 enable extrapolation of experimental results of aerosol deposition to humans (Supplementary figure 3).
270 Presently, this model has mainly been used to evaluate nebulization of topically-acting small drugs (e.g.
271 antibiotics) during artificial ventilation (Rouby et al., 2012). Indeed, pigs are becoming an increasingly
272 important species for translational research and may be a relevant model in which to test the efficacy of anti-
273 infectious biotherapeutics. A major advance was made in the field of respiratory medicine with the generation of
274 the porcine cystic fibrosis model (Guillon et al., 2015a; Rogers et al., 2008). Sheep have also been used, but less
275 frequently, as a model for aerosol delivery during mechanical ventilation. One of the best examples has been
276 provided during the preclinical development of a 45kDa recombinant alpha anti-trypsin (rAAT) that
277 demonstrated the feasibility of using aerosolization to the pulmonary surface to administer rAAT in sheep
278 (Hubbard et al., 1989). Direct intra-tracheal administration of liquid or powder aerosol is also possible in
279 intubated large animals thanks to dedicated sprayers (Guillemineault et al., 2014). Dry powder aerosols can be

280 administered using a Dry Powder Insufflator™ without any concerns for tolerance considerations associated
281 with the device (Guillon et al., 2016); the volume of insufflated air generated by the device is considerably
282 lower than the animal's tidal volume and therefore does not cause lung lesions (Guillon et al., 2012). Dry
283 powder inhaler devices have also been developed for use in beagle dogs via oro-tracheal intubation (Sellers et
284 al., 2015).

285

286 *2.3 Aerosol delivery methods in animals and transposition to human*

287

288 It is important to keep in mind that inhalation therapy is atypical in its difficulty to find relevant animal
289 models, compared to other routes of delivery. Pulmonary delivery is probably the most challenging route in
290 animal models because drug delivery is highly dependent of the anatomy and respiratory physiology of the
291 animal species. Drug deposition in animal is also affected by the aerosol-generating systems, which poorly
292 mimic the aerosol distribution encountered in human, even when using devices intended for human.
293 Consequently, (i) the gap between human and animal models anatomy and respiratory pattern, and (ii) the
294 differences between devices engineered for experimental purpose and actual human devices, are two important
295 limiting factors for successful translation to the clinic. It is clear that further refinement of current experimental
296 models is necessary. The development of animal devices that would reproduce the distribution of the drugs in
297 human, taking into account the respiratory parameters, the physiological properties and anatomy of the lungs of
298 the animal, may be helpful for the translation of results into the clinics.

299 Despite those limitations, two animal models of aerosol delivery have a high translational potential for
300 specific clinical applications and should be highlighted. First, aerosol delivery during invasive mechanical
301 ventilation in large mammals, such as pigs, is particularly relevant to mimic aerosol delivery during invasive
302 mechanical ventilation in humans. As the oropharynx is bypassed by the tracheal probe, the anatomic
303 differences are not anymore issues. Moreover, ventilators settings could be identical between humans and pigs.
304 In a recent systematic review assessing the aerosol delivery during invasive mechanical ventilation according to
305 the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, 36 studies
306 were finally included among 234 articles assessed for eligibility, and comprised 26 clinical studies and 10
307 experimental studies (Dugernier et al., 2017). Nine of these experimental studies were performed on pig models
308 and one a dog model. So far, these models have never been used for the development of a biotherapeutic. The
309 second relevant model is the macaque (*Macaca Fascicularis*), in the weight range of a full-term newborn
310 human, which enable to make accurate prediction of aerosol lung deposition in infant (Dubus et al., 2005;
311 Réminiac et al., 2017). No modification of human facemask is necessary; infant are also nose breather not able
312 to synchronize inspiratory time with drug delivery.

313

314 **3. Methods to assess lung deposition after aerosol delivery**

315

316 Distribution and deposition of the aerosol in the different regions of the lung depend on particle
317 properties, but are also affected by the subject's breathing pattern pathophysiological context. Hence, the dose
318 of the delivered aerosol is likely to vary substantially in the lung and imaging provides a non-invasive way to
319 measure *in vivo* the regional distribution of inhaled drugs.

320 Assessment of aerosol deposition in airways is mainly performed using imaging techniques which are
321 summarized in Table 1. Among them, planar (2D) scintigraphy is the most relevant and standardized method,
322 providing robust results (Newman et al., 2012). It relies on the use of either direct or indirect radiolabeling of
323 the material to be measured using a gamma camera, and provides a 2D image of the distribution of radioactivity
324 in the airways. Technetium-99m (^{99m}Tc) is the most common radioactive element used for labeling due to its
325 suitable half-life regarding the duration of image acquisition and radio-protection. It can be also used in
326 combination with diethylene triamine penta-acetic Acid (DTPA) to trace the unlabeled drug and avoids quick
327 ^{99m}Tc diffusion into the systemic circulation (Guillon et al., 2015c).

328 Nebulizer delivery methods are well adapted to ^{99m}Tc -DTPA 2D scintigraphy because the active drug is
329 directly accessible for labeling (Behr et al., 2009). Biotherapeutics can also be used as theranostic agents
330 through the attachment of a radiolabel chelator to the biotherapeutic. For antibodies, the use of the short-lived
331 ^{99m}Tc improves physical imaging because of high proton flux, high resolution and low dosimetry (Andersson et
332 al., 2016). It is also particularly relevant for Fab fragments which exhibit accelerated clearance resulting in
333 better target-background ratio (Wahl et al., 1983). Quality specifications of a labeled biopharmaceutical must be
334 assessed and in particular the conservation of its biological properties (Eisenhut and Haberkorn, 2006). In
335 addition, the characterization of peptide impurities following labeling or instability processes is mandatory as
336 such by-products can generate toxic or unexpected pharmacological effects. Labeling is more challenging when
337 complex devices or formulations are involved, such as pMDIs or DPIs, as this requires manufacture and filling
338 of the radioactive formulation into the delivery device (Aug et al., 1991). The validation of aerosol drug
339 radiolabeling and radiotracing must be done prior to the 2D gamma camera imaging. It must be demonstrated
340 that the radiolabel or radiotracer does not affect the aerosol characteristics compared to the non-labeled system
341 (Guillon et al., 2015c). Recommendations have been established for the validation of a
342 radiolabeling/radiotracing method, utilizing similar criteria to those recommended by the EMA guidelines and
343 the ISAM/IPAC-RS Workshop Report (European Medicines Agency Committee for Medicinal Products for
344 Human Use, n.d.).

345 Multiple planar images at different positions around the body can be processed to generate a 3D-image
346 of the location of a radiolabeled drug. This principle is at the basis of both positron emission tomography (PET)
347 and single-photon-emission computed tomography (SPECT) imaging. Before PET became available, SPECT
348 was the primary imaging modality, especially to assess mAb distribution. SPECT imaging relies on similar
349 radioelements as planar scintigraphy, including ^{99m}Tc , ^{111}In or ^{131}I . Both fragment and full-length mAb have
350 been labeled and the rationale supporting the choice of the radioelement is based on the matching between its
351 half-life and the plasma residence time of the mAb. For example, long-lived ^{111}In or ^{131}I have been used to label
352 whole antibodies, while the short-lived ^{99m}Tc has been used to label antibody fragments and all have been
353 successfully imaged in humans (Goldenberg et al., 1978; Machac et al., 2002; Nagengast et al., 2011; Yao et al.,
354 2007). PET uses radioisotopes that emit a positively charged electron, which when once annihilated produces
355 two gamma rays in exactly opposite directions allowing for a better resolution than SPECT. Among the PET
356 radioisotopes, ^{89}Zr has been widely used in the clinic for labeling anti-tumor mAbs. Short-lived positrons like
357 ^{18}F or ^{76}Br are mainly used for the imaging of antibody fragments and small antibody-like molecules (Lamberts
358 et al., 2015). Of note, scintigraphy acquisition required careful adjustments and corrections that are not detailed
359 here. These correcting factors may vary depending on the anatomical features of the animal species (Frédéric

360 Gagnadoux et al., 2005; Gagnadoux et al., 2006; Guillon et al., 2014). In many cases, anatomical images can be
361 added to deposition images using X-ray computed tomography (CT) or magnetic resonance imaging (MRI) to
362 provide a better spatial distribution of the aerosol and evaluation of aerosol treatments (Conway et al., 2013).
363 These methods provide considerable amounts of information in terms of aerosol distribution in the lung and they
364 are mainly used for basic scientific research. Nevertheless, they are more complex methods than 2D
365 scintigraphy using a gamma camera and the algorithms for calculating aerosol deposition are less well
366 established. MRI, on its own, has also been considered in assessing lung aerosol deposition and has the
367 advantage of measurement without radioactive agent exposure (Thompson and Finlay, 2012). However, the
368 oxygen in the air that filled lungs complicates MRI, thus making necessary helium inhalation to enhance
369 contrast in the lungs. For a long time, the signal intensity of the contrast agent in the lung and the lack of a
370 standardized method of calculation limited MRI imaging to accurately measure aerosol deposition in the lung
371 (H. Wang et al., 2016). A recent method using ultra-short echo (UTE) sequences and gadolinium-labeled aerosol
372 resulted in an enhanced signal in the lung parenchyma, compatible with a precise quantitation of regional
373 distribution of the aerosol deposition.

374

375 **4. Methods to assess PK and toxicity after aerosol delivery**

376

377 Although inhaled drug deposition and lung anatomy/physiology may be different between animals and
378 humans, making extrapolation across species difficult, animal models are crucial to analyze the PD, PK and
379 toxicity of aerosolized drugs. The methods used for pulmonary delivery, reviewed above, are critical because
380 they involve variable drug losses in the delivery system and into the environment, specific sites of deposition
381 (within or outside the respiratory tract), all of them altering therapeutic efficacy, PK and toxicity of the inhaled
382 drug.

383

384 *4.1 Determination of drug concentration in blood and lung environment*

385

386 *4.1.1 Determination of aerosolized-drug in the bloodstream*

387 As drug concentration cannot be easily assessed in the lung, PK studies are done by measuring the
388 levels of drug in the systemic circulation, both for local and systemically acting drugs. However, for drugs
389 acting locally, high serum concentrations are usually related to unwanted systemic exposure and potential safety
390 concerns, and thus provide little information on efficacy. Anatomical lung differences, mucociliary clearance
391 rates and the number of alveolar macrophages, which may all contribute to drug clearance, are known to vary
392 significantly between species and may influence PK determination. PK studies assessing drug concentrations in
393 blood are performed by collecting blood from a vein or alternatively via implantation of a catheter to avoid
394 repeated venipuncture. Although NHPs are the closest to humans, with similar anatomy, physiology and
395 genetics, rodent models are often used for preclinical PK studies. Nevertheless, mice are technically challenging
396 as a species to undertake multiple blood sampling from lung dosimetry studies. In larger animals, multiple blood
397 sampling is no longer an issue and allows a more accurate non-destructive profiling of the systemic
398 serum/plasma levels in each animal. PK parameters describing the absorption, distribution and elimination of
399 the drug and its bioavailability can be generated from appropriate mathematical methods (compartmental and/or

400 non-compartmental analysis) and using the concentration measurements in plasma at relevant time points.
401 However, indirect modelling of lung concentrations from drug concentration-time profiles in plasma using
402 mathematical compartmental models, taking into account the delivery route may not be enough to predict the
403 clinical outcome (Eichler and Müller, 1998; Paintaud, 2009; Presant et al., 1994). Indeed, many drugs, such as
404 anti-infective agents, biotherapeutics and controlled release systems designed to prevent systemic exposure, do
405 not distribute uniformly in different tissues and the dose-effect relationship is dependent on the distribution of
406 the drug at the target site. Analyses of the drug concentration in the bloodstream may also be affected by the
407 swallowed portion of the drug and subsequent absorption across the gastrointestinal tract. Clearance from the
408 lung to the blood has been shown to be a linear function of the molecular weight of the drug regardless of the
409 species (Matsukawa et al., 1997). Once in the systemic compartment, biopharmaceuticals like full-length
410 immunoglobulin, with a molecular weight of 150kDa remain in the circulation for 3-4 weeks and are slowly
411 metabolized. Monovalent fragments (e.g, single-chain antibody or scFv) have a blood clearance of ~10h with
412 primarily renal excretion of 2-4h. Molecules with intermediate weight, ~70kDa (the threshold for glomerular
413 filtration) have longer residence times. These discrepancies are therefore another strong reason for developing
414 better methods to measure drug concentrations in the lung tissue to understand the distribution of drugs in the
415 relevant anatomical compartment.

416

417 *4.1.2 Determination of aerosolized-drug concentration in the lungs*

418 Drug concentration can be measured in the airways and epithelial lining fluid (ELF) usually by
419 bronchoalveolar lavage (BAL), a procedure which consists of injecting saline solution into the lungs, followed
420 by re-aspiration. BAL can be performed on the whole lungs for small animals or portions of the lungs for larger
421 species after euthanasia, or on live animals, usually non-rodents, via bronchoscopy (Mankikian et al., 2014).
422 Because injection of solutions into the lungs interferes with local drug concentrations and thus PK parameters,
423 BAL usually only gives useful information for one time point in one animal. However, it is possible in larger
424 animals, to collect, throughout the experiment, several BAL samples from different respiratory tract regions,
425 using bronchoscopy or tracheal swabbing through the nose (Jacobson et al., 2017). In this case, it is important to
426 use an endogenous marker diffusing passively throughout the different tissue compartments as an internal
427 reference (Kipnis, 2005). Alternatively drug concentration can be measured in the lung tissue, at autopsy, which
428 requires resection, homogenization of lung tissue and extraction of the drug with the appropriate solvent. For
429 peptide-based therapies, the main drawback is that their lung residency may be hindered by their instability due
430 to the presence of proteinases.

431

432 *4.1.3 Imaging methods and microdialysis*

433 Although imaging techniques are widely used to follow drug distribution, they are rarely employed for
434 PK studies of aerosolized drugs in preclinical studies (Anderson, 2000; Fok et al., 1999; Guilleminault et al.,
435 2014; Weinstein et al., 2012). Depending on the imaging techniques used, the drug is conjugated to the most
436 relevant tracer, which involves labeling and purification of the drug conjugate. The major caveats for PK
437 imaging include short tracer half-life that may limit kinetic follow up, in particular for biotherapeutics, such as
438 antibodies with long half-life. Another limitation is the possible release of the tracer *in vivo* and passive
439 diffusion into different tissues, and impairment of drug binding to its target antigen and/or transport receptor due

440 to its conjugation to the tracer. Imaging techniques involve costly equipment and are associated with technical
441 challenges to conjugate the drug, which limit their wider use for PK studies. We previously described the fate of
442 a mAb, labeled with a fluorophore and delivered by the airways, using Near Infrared Fluorescent Imaging
443 (NIRF). Although accurate quantification remains challenging, it was possible combining 3D *in vivo* imaging
444 and 2D quantification on *ex vivo* lung specimens (Guillemineault et al., 2014).

445 In vivo microdialysis is an interesting and well-established semi-invasive sampling technique that has
446 been used to study PK of drugs in various tissues (Brunner and Langer, 2006; Dhanani et al., 2010; Elmquist
447 and Sawchuk, 1997; Zeitlinger et al., 2005). As this technique does not withdraw any body fluids or
448 compromise homeostasis, it allows the repeated measurement of the unbound and/or soluble drug in the
449 interstitial space from the same animal, which substantially reduces the number of animals required for
450 preclinical PK studies. This method is based on the use of probes with a semi-permeable membrane, which are
451 implanted in the tissue of interest and continuously perfused with a physiological solution (perfusate) at a very
452 slow flow rate (usually 1 to 10 $\mu\text{L}/\text{min}$). The implantation of microdialysis probes is possible under direct vision
453 during thoracic surgery to avoid pneumothorax and collapse of the lung, and to date no major peripheral tissue
454 trauma has been reported (de la Peña et al., 2000). The dialysate is collected at timed intervals and
455 substances/drugs in the interstitial space fluid diffuse passively through the membrane pores, along their
456 concentration gradient (Supplementary figure 4). Although, it has been used extensively to follow the kinetics of
457 neurotransmitter levels in neuroscience research, and to monitor small drugs in peripheral tissues, it is now
458 possible, thanks to higher molecular cut-off membrane and push-pull methods, to also analyze the fate of larger
459 molecules, such as proteins. However, because the dialysate volume is small, in the microliter range, it requires
460 highly sensitive methods for sample analysis. An additional limitation of microdialysis is the proper calibration
461 of the microdialysis probes because the analyte diffusion is performed under non-equilibrium conditions and the
462 concentration measured in the dialysate will reflect only a fraction of the concentrations in the interstitial fluid
463 surrounding the catheter (Dhanani et al., 2010). Microdialysis has been shown to be feasible for most tissues,
464 including the lungs, and in different species (de la Peña et al., 2000; Zeitlinger et al., 2005). Notably, it has been
465 applied to the measurement of both non-infective and anti-infective agents with success, demonstrating its
466 relevance for intra-bronchial PK measurement of drugs in the lungs (de la Peña et al., 2000; Zeitlinger et al.,
467 2005). Microdialysis with monoclonal antibodies has recently been shown feasible (Jadhav et al., 2017).

468 469 *4.1.4 Influence of pathological conditions on inhaled drug concentration in the lung*

470 Disease states have to be taken into consideration for the accurate determination of drug deposition in
471 the lung, especially those characterized by bronchoconstriction, inflammation and airway narrowing.
472 Respiratory diseases, such as cystic fibrosis and chronic obstructive pulmonary disease exhibit changes in the
473 architecture of the lung with obstruction of the airways, mucus hypersecretion and modification in the
474 bifurcation angles, which may alter the distribution patterns of therapeutic aerosols, in particular those
475 containing high-molecular weight protein therapeutics like mAbs. Pro-fibrotic diseases such as idiopathic
476 pulmonary fibrosis or emphysema, are characterized by the overexpression of proteases in the ELF, which may
477 cause protein therapeutic degradation and hinder drug penetration to the epithelium. ELF also contains
478 surfactant that have been shown to interact with exogenous proteins promoting their aggregations (Nag et al.,
479 2007). Myeloid cells such as alveolar macrophages may also participate in the regulation of inhaled drug.

480 Indeed, they have been described as barrier cells to the transport of large protein (>40Kda) from the airway into
481 the parenchyma (Lombry et al., 2004). During the acute phase of lung inflammation, alveolar macrophages
482 undergo rapid apoptosis, thereby reducing their interactions with inhaled drug. This may impact inhaled mAb
483 clearance because alveolar macrophages express FcRn, which may prevent intracellular degradation of inhaled
484 mAbs, after they deposited in the airways. Finally, inflammation injures both epithelial and endothelial lung
485 barriers promoting leukocyte extravasation and infiltration of vascular fluid. This increased pulmonary
486 microvascular permeability may dilute the drug within the lungs. On the other hand, inhaled drug leakage into
487 the systemic circulation may occur if the bronchoalveolar barrier is disrupted. This was observed for an inhaled
488 mAb, after an accidental acute lung injury due to gastric inhalation during an aerosoltherapy session
489 (Guilleminault et al., 2014).

490

491 *4.2 Scaling-up of animal results to determine first-in-man dose, for drug delivered by inhalation*

492

493 First-in-man dose estimation from pre-clinical pharmacology data for systemically administered drugs is based
494 from the common use of allometric dose scaling (Nair and Jacob, 2016). Allometric scaling approaches allows
495 interspecies correlation with an empirical calculated pharmacologic parameter and is the standard way to
496 approximate equivalent interspecies doses unless extrapolating doses based on other parameters is known to be
497 more appropriate. For drug delivered by inhalation, scientific data to support the assumption that allometric
498 scaling is useful to predict the dose is lacking. In a recent review (Phillips, 2017), allometric scaling exponent
499 has been retrospectively calculated from experimental rodent data and the known inhaled clinical dose that needs
500 to be deposited in the human lung. The author studied four inhaled compounds currently used clinically
501 (mometasone, budesonide, salbutamol, ipratropium) and assumed that in all rodent, canine, nonhuman primate
502 and human, the pulmonary deposition fractions were 10%, 25%, 30%, and 40%. The allometric interspecies
503 scaling equation obtained was: $Y_h = Y_a (M_a / M_h)^{-b}$. Where Y_h is the human drug dose (μg), M_h is the human
504 body mass (kg), Y_a is the animal drug dose (μg), M_a is the animal body mass (kg), b is the allometric exponent.
505 The average of the allometric exponents obtained in mouse, rat and human supports the current method of
506 scaling using a fixed allometric exponent of 0.67 (Phillips, 2017). The utility of fixed exponent allometric
507 scaling to project an inhaled human dose is pragmatic and could have a place in the drug development decision
508 making process; however, it should be used cautiously as important simplifications were required (i.e. the
509 pulmonary deposition fractions) and this calculation being performed on a small dataset ($n=4$). Moreover, it may
510 not be recommended for inhaled biotherapeutics, such as mAbs. Although the predictive value of allometry for
511 mAbs is admitted with monkey data when mAb PK profile is linear, scaling up from animals to human is more
512 complicated for mAbs with nonlinear PK because species differences (antigen density, antigen/FcRn interaction
513 with mAbs, ...) should be considered (Kamath, 2016; J. Wang et al., 2016) and require more mechanistic
514 approaches (PKPD models, ...).

515

516 *4.3 Toxicology of inhaled biopharmaceuticals*

517

518 Aerosolized drugs may potentially have adverse effects ranging from subtle changes in respiratory
519 function to alterations in lung biochemistry, immunology, permeability and potentially mortality. The accurate
520 determination of the dose reaching the lung is of particular importance, but as for pulmonary delivery or PK-PD

521 studies, toxicology analysis of inhaled drugs will be susceptible to innate specificity of the animal model used
522 (Figure 1), as well as the exposure system and the calculation method chosen.

523 As highlighted in Section I.B, it is generally accepted that the drug distribution throughout the lung will
524 not be comparable to aerosol administration and that the toxicological profile of the aerosolized drug will be
525 different to that of compounds administered intra-tracheally. Drugs or drug formulations are typically
526 administered either as a nebulized solution/suspension, or as a dry powder (Owen, 2013). Currently, dry powder
527 formulations comprise the majority of inhaled formulations under development. Due to the impracticalities of
528 using clinical dry powder inhaler devices in toxicology studies, alternative aerosol generator devices have been
529 designed for dosing of nonclinical species. Two systems are currently in use to generate dry powder aerosols for
530 simultaneous dosing of typically up to 24 rodents in nose-only exposure cones or a variable number of dogs
531 using facial masks: the Wright dust feeder and the relatively recent capsule-based aerosol generator (Armstrong
532 et al., 2015; Paul et al., 2012). Regulatory studies based on Wright dust feeder always use aerosol
533 administration, because this dosing method is considered closest to therapeutic dosing. In comparison, the
534 capsule-based aerosol generator method is able to deliver similar lung doses over a large dosing range, but
535 utilizes a lower amount of starting material and is therefore suitable for expensive compounds with limited
536 available quantities (Paul et al., 2012).

537 The species used for regulatory toxicology studies are informed by regulatory guidelines, which require
538 all assessments to be made in a rodent and non-rodent species, typically the rat and dog, although NHPs are also
539 increasingly being used. It has been observed that certain forms of toxicity, both systemic and local, may be
540 specific to the animal model and have little relevance for humans. Species-specific local toxicity or irritancy can
541 often be observed in the nasal cavity of many experimental animals, especially obligate nasal breathers. This
542 form of adverse event is typically not relevant for most inhaled products (i.e. pMDIs and dry powder inhalers)
543 which are delivered via the oral cavity with no nasal exposure (Owen, 2013). However, nasal effects may be
544 relevant for certain nebulized drugs for intended use in neonatal populations, as infants are also nasal breathers.
545 Another adverse event often observed in rats, but not relevant for humans, is squamous metaplasia of the larynx.
546 This local inflammation results from a high impaction of drug in the rat larynx following inhalation exposure,
547 due to the nearly linear position of larynx behind the nasal cavity in rats. The immune response to the deposition
548 may finally dictate the safety of the inhaled biotherapy.

549 Species-specific adverse events in the lung itself are rarer. It is widely recognized that rats are
550 especially susceptible to lung overload with poorly soluble particulates. Lung overload occurs when the
551 clearance mechanisms for removal of particulates, typically by macrophages, but also via particle entrapment in
552 the mucus layer and removal via the mucociliary elevator, are saturated. Related to the phenomenon of lung
553 overload in rats, is the effect of poorly soluble drug particles on alveolar macrophage populations. It has been
554 reported that focal macrophage accumulations often with a “foamy” appearance are a frequent observation in
555 non-clinical toxicology studies of dry powder formulations not only in rats, but non-rodent species as well
556 (Forbes et al., 2014; Lewis et al., 2014). Above certain particle burdens, a progressive neutrophilic inflammation
557 will develop with infiltration of inflammatory cells and elevated pro-inflammatory cytokine production. Chronic
558 inflammation may lead to local tissue damage and fibrosis. In rats this can progress to neoplasia, although this
559 has not been observed in humans or other nonclinical toxicology species (Owen, 2013; Wolff, 2015). The
560 immunogenicity of biotherapeutics may also be an important issue. Anti-drug antibodies (ADA) may be

561 generated and have detrimental impact on drug safety, efficacy and pharmacokinetics (Smith et al., 2016).
562 Although the induction of ADA is in many cases harmless, serious consequences might occur, as shown in
563 human, by the current epidemic of the antibody-induced severe anemia that is associated with the use of a
564 specific form of recombinant erythropoietin (Schellekens, 2002). Structural alterations of proteins secondary to
565 the inhalation process can potentially favor the generation of aggregates that could augment protein-specific
566 immune response and eventually lead to the formation of ADA (Sauerborn et al., 2010). It is acknowledged that
567 ADA formation in nonclinical species may not be predictive of clinical immunogenicity. However, it is
568 accepted practice to assess whether differences in the PK/PD profile of the biopharmaceutical between the first
569 and last dose occur or whether there is evidence of immune-mediated toxicity in nonclinical studies. In such
570 cases, ADA investigations may be warranted (McElroy et al., 2013).

571 A further issue of relevance for the design of safety assessment studies for biopharmaceuticals is the
572 impact of exaggerated pharmacology. Since the toxicity of many biopharmaceutics is often related to their
573 mechanism of action, for example hypoglycaemia following insulin administration, the dose increases routinely
574 used in toxicology studies may induce a toxic pharmacologic response, which may be independent of the
575 intrinsic toxicology. For this reason, ICH S6 guidelines require pharmacodynamic endpoints in nonclinical
576 toxicology study design (McElroy, 2013). In such cases, the intrinsic and biological toxicity can and should also
577 be assessed in the pharmacological species of interest, as well as animal models of disease. This can help to
578 define whether the toxicity profile of the biopharmaceutical is primarily defined by intrinsic toxicity or
579 exaggerated pharmacology (Cavagnaro, 2013).

580

581 **5. Future directions and conclusion**

582

583 Extrapolating data from animal studies to humans is a major challenge which is particularly true for
584 inhaled medicines delivered through the pulmonary route. Because of the complexities and interspecies
585 physiological, anatomical and metabolic differences in the respiratory tract, it can be difficult to bridge animal
586 data to human patients inhaling a drug. This does not mean that animal models for aerosol drug delivery are
587 irrelevant. They have contributed significantly to the development of all currently used pharmacological classes
588 of drug that are delivered by topical administration to the lung, and they are helping with the development of
589 inhaled biotherapeutics. From a regulatory point of view they are mandatory, and both rodent and non-rodent
590 (usually dog or NHP) species are required for this purpose. Rodents are widely used in preclinical studies and
591 useful, in particular to decipher mechanisms of action considering the availability of a large number of
592 tools/reagents and transgenic models, particularly in mice. However, it is now assumed that the expansion in the
593 use of mice for PD studies, over the past decade, has not been associated with a marked increase in the number
594 of effective new classes of inhaled drugs. The predictability of murine models is particularly questioned for
595 biotherapeutics, and accordingly, there would seem to be an urgent need to reassess the use of the most
596 appropriate non-clinical species, depending on the class of the drug, to predict safety and efficacy in man.
597 Although there are ethical considerations, larger mammals such as NHPs may be more predictable for inhaled
598 biologics being closer to humans, on a biochemical, cellular and immunological point of view. Moreover, those
599 drugs often display a high specificity for their target raising further concerns on the relevant species to select for
600 preclinical development.

601 The difficulty to translate promising drug candidates for inhalation from animal models to humans
602 underlines the need for more predictive models. Although the utility of *in vivo* studies is sometime questioned,
603 animals remain irreplaceable so far, because current *in vitro/ex vivo* approaches still struggle to replicate the
604 complex environment of the human respiratory tract and encounter similar limits as those of animal models
605 when it comes to aerosol delivery. However, the progresses of the latest technologies are encouraging, offering
606 great promises for the development of inhaled biotherapeutics. Among them, the following can be emphasized.
607 Airways epithelial cells cultured at the air-liquid interface reproduce a physiological respiratory epithelium and
608 may be combined with a dose-controlled aerosol-cell exposure system (ALICE CLOUD) to evaluate
609 transepithelial absorption of aerosolized protein therapeutic (Röhm et al., 2017). Additional applications with
610 this delivery system may include the impact of inhaled biotherapeutics on airways epithelium integrity. Organ-
611 on-chip technology recapitulates the dynamic tissue-tissue interactions on a microdevice. As an example, lung-
612 chips integrate several tissue compartments (endothelium, epithelium) where cells are submitted to the
613 mechanical and fluidic forces they experienced in the body, and can be exposed to exogenous agents (cigarette-
614 smoke, pathogens,...) to mimic pathological conditions (Benam et al., 2016; Huh et al., 2010). Future
615 developments to connect this biomimetic microsystem to aerosol delivery systems may be helpful to study the
616 pharmacodynamics and PK parameters with inhaled biotherapeutics. Today, *in silico* approaches provide
617 realistic 3D micro-models of the human respiratory system that can be combined with simulation techniques,
618 like computational fluid dynamics, to explore respiratory airflows and aerosol transport in the lungs, useful to
619 predict inhaled drug deposition (Hofemeier et al., 2017). Thus, hybrid modeling using these emerging
620 technologies could be a solution to refine existent animal models of aerosol delivery.

621 Although inhalation is clearly not suited for all medicines and has to be chosen based on solid scientific
622 arguments, it is time to reconsider the most judicious use of non-clinical species in the development of inhaled
623 medicines to ensure improved rates of successful translation to the clinic. Rather than opposing *in vivo* models
624 with other approaches, future challenges will be probably to implement complimentary approaches that more
625 precisely recapitulate the human respiratory complexity and aerosol delivery in order to help future preclinical
626 developments of inhaled biotherapeutics.

627
628

629 **Table 1**
 630

Comparison of imaging techniques for aerosol-based applications		
Technique	Advantages	Disadvantages
Planar scintigraphy	Less expensive Validated methods for quantification Available standardized operating procedures	Only 2-D representation of lung anatomy
PET	Better resolution 3-D representation of lung anatomy Co-acquisition with MRI/CT	Use of radio-labeled element Limited half-life of positron emitters Expensive facilities
SPECT	Better resolution 3-D representation of lung anatomy Co-acquisition with MRI/CT	Use of radio-labeled element Long imaging time Complex quantification Expensive facilities
MRI	Promising technology, but still in development phase	

631

632 **References**

- 633 Anderson, P.J., 2000. Assessment end points for inhaled drug delivery. *Respir. Care* 45, 737–
634 755.
- 635 Andersson, K.G., Oroujeni, M., Garousi, J., Mitran, B., Ståhl, S., Orlova, A., Löfblom, J.,
636 Tolmachev, V., 2016. Feasibility of imaging of epidermal growth factor receptor
637 expression with ZEGFR:2377 affibody molecule labeled with ^{99m}Tc using a peptide-
638 based cysteine-containing chelator. *Int. J. Oncol.* 49, 2285–2293.
- 639 Armstrong, R., Rodgers, D., Gutteridge, C., Paul, G., Moore, S., Jordan, S., Meecham, K.,
640 2015. Efficacy of an Inhaled PDE4 Inhibitor, GSK256066, Delivered by a Novel Dry
641 Powder Pre-Clinical Inhalation Delivery System in the Acute Cigarette Smoke
642 Induced Pulmonary Inflammation Model. *Am. Thorac. Soc. Int. Conf. Abstr.* A4255–
643 A4255.
- 644 Asgharian, B., Price, O., McClellan, G., Corley, R., Einstein, D.R., Jacob, R.E., Harkema, J.,
645 Carey, S.A., Schelegle, E., Hyde, D., Kimbell, J.S., Miller, F.J., 2012. Development
646 of a rhesus monkey lung geometry model and application to particle deposition in
647 comparison to humans. *Inhal. Toxicol.* 24, 869–899.
- 648 Aug, C., Perry, R.J., Smaldone, G.C., 1991. Technetium ^{99m} radiolabeling of aerosolized
649 drug particles from metered dose inhalers. *J. Aerosol Med. Off. J. Int. Soc. Aerosols*
650 *Med.* 4, 127–138.
- 651 Babin, A.L., Cannet, C., Gérard, C., Saint-Mezard, P., Page, C.P., Sparrer, H., Matsuguchi,
652 T., Beckmann, N., 2012. Bleomycin-induced lung injury in mice investigated by
653 MRI: model assessment for target analysis. *Magn. Reson. Med.* 67, 499–509.
- 654 Balashazy, I., Hofmann, W., Heistracher, T., 2003. Local particle deposition patterns may
655 play a key role in the development of lung cancer. *J. Appl. Physiol. Bethesda Md*
656 *1985* 94, 1719–1725.
- 657 Bassett, L., Troncy, E., Robichaud, A., Schuessler, T.F., Pouliot, M., Ascah, A., Authier, S.,
658 2014. Non-invasive measure of respiratory mechanics and conventional respiratory
659 parameters in conscious large animals by high frequency Airwave Oscillometry. *J.*
660 *Pharmacol. Toxicol. Methods* 70, 62–65.
- 661 Behr, J., Zimmermann, G., Baumgartner, R., Leuchte, H., Neurohr, C., Brand, P., Herpich,
662 C., Sommerer, K., Seitz, J., Menges, G., Tillmanns, S., Keller, M., Munich Lung
663 Transplant Group, 2009. Lung deposition of a liposomal cyclosporine A inhalation
664 solution in patients after lung transplantation. *J. Aerosol Med. Pulm. Drug Deliv.* 22,
665 121–130.
- 666 Belser, J.A., Gustin, K.M., Katz, J.M., Maines, T.R., Tumpey, T.M., 2015. Comparison of
667 traditional intranasal and aerosol inhalation inoculation of mice with influenza A
668 viruses. *Virology* 481, 107–112.
- 669 Benam, K.H., Novak, R., Nawroth, J., Hirano-Kobayashi, M., Ferrante, T.C., Choe, Y.,
670 Prantil-Baun, R., Weaver, J.C., Bahinski, A., Parker, K.K., Ingber, D.E., 2016.
671 Matched-Comparative Modeling of Normal and Diseased Human Airway Responses
672 Using a Microengineered Breathing Lung Chip. *Cell Syst.* 3, 456–466.e4.
673 <https://doi.org/10.1016/j.cels.2016.10.003>
- 674 Brunner, M., Langer, O., 2006. Microdialysis versus other techniques for the clinical
675 assessment of in vivo tissue drug distribution. *AAPS J.* 8, E263-271.
- 676 Cavagnaro, J.A., 2013. *Preclinical Safety Evaluation of Biopharmaceuticals: A Science-
677 Based Approach to Facilitating Clinical Trials.* John Wiley & Sons.
- 678 Chandener, J., Bernard, S., Montharu, J., Bailly, E., Fetissof, F., de Monte, M., Desoubieux,
679 G., Diot, P., Richard-Lenoble, D., 2009. The utility of a nebulised intra-tracheal rat
680 model of invasive pulmonary aspergillosis. *Mycoses* 52, 239–245.
681 <https://doi.org/10.1111/j.1439-0507.2009.01695.x>

682 Chen, X.-J., Zhu, J.-B., Wang, G.-J., Zhou, M.-X., Xin, F.-M., Zhang, N., Wang, C.-X., Xu,
683 Y.-N., 2002. Hypoglycemic efficacy of pulmonary delivered insulin dry powder
684 aerosol in rats. *Acta Pharmacol. Sin.* 23, 467–470.

685 Conway, J., Fleming, J., Bennett, M., Havelock, T., 2013. The co-imaging of gamma camera
686 measurements of aerosol deposition and respiratory anatomy. *J. Aerosol Med. Pulm.*
687 *Drug Deliv.* 26, 123–130.

688 Crapo, J.D., Young, S.L., Fram, E.K., Pinkerton, K.E., Barry, B.E., Crapo, R.O., 1983.
689 Morphometric characteristics of cells in the alveolar region of mammalian lungs. *Am.*
690 *Rev. Respir. Dis.* 128, S42-46.

691 Cryan, S.-A., Sivadas, N., Garcia-Contreras, L., 2007. In vivo animal models for drug
692 delivery across the lung mucosal barrier. *Adv. Drug Deliv. Rev.* 59, 1133–1151.

693 de la Peña, A., Liu, P., Derendorf, H., 2000. Microdialysis in peripheral tissues. *Adv. Drug*
694 *Deliv. Rev.* 45, 189–216.

695 De Vooght, V., Vanoirbeek, J.A.J., Haenen, S., Verbeken, E., Nemery, B., Hoet, P.H.M.,
696 2009. Oropharyngeal aspiration: an alternative route for challenging in a mouse model
697 of chemical-induced asthma. *Toxicology* 259, 84–89.

698 Dentice, R., Elkins, M., 2016. Timing of dornase alfa inhalation for cystic fibrosis. *Cochrane*
699 *Database Syst. Rev.* 7, CD007923. <https://doi.org/10.1002/14651858.CD007923>

700 Derelanko, M.J., Hollinger, M.A., 1995. *Handbook of Toxicology, Second Edition.* CRC
701 Press.

702 Desoubeaux, G., Reichert, J.M., Sleeman, M., Reckamp, K.L., Ryffel, B., Adamczewski, J.P.,
703 Sweeney, T.D., Vanbever, R., Diot, P., Owen, C.A., Page, C., Lerondel, S., Le Pape,
704 A., Heuze-Vourc'h, N., 2016. Therapeutic monoclonal antibodies for respiratory
705 diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours,
706 France. *mAbs* 8, 999–1009.

707 Dhanani, J., Roberts, J.A., Chew, M., Lipman, J., Boots, R.J., Paterson, D.L., Fraser, J.F.,
708 2010. Antimicrobial chemotherapy and lung microdialysis: a review. *Int. J.*
709 *Antimicrob. Agents* 36, 491–500.

710 Dubois, A.V., Midoux, P., Gras, D., Si-Tahar, M., Bréa, D., Attucci, S., Khelloufi, M.-K.,
711 Ramphal, R., Diot, P., Gauthier, F., Hervé, V., 2013. Poly-L-Lysine compacts DNA,
712 kills bacteria, and improves protease inhibition in cystic fibrosis sputum. *Am. J.*
713 *Respir. Crit. Care Med.* 188, 703–709. <https://doi.org/10.1164/rccm.201305-0912OC>

714 Dubus, J.C., Vecellio, L., De Monte, M., Fink, J.B., Grimbert, D., Montharu, J., Valat, C.,
715 Behan, N., Diot, P., 2005. Aerosol deposition in neonatal ventilation. *Pediatr. Res.* 58,
716 10–14. <https://doi.org/10.1203/01.PDR.0000156244.84422.55>

717 Dugernier, J., Ehrmann, S., Sottiaux, T., Roeseler, J., Wittebole, X., Dugernier, T., Jamar, F.,
718 Laterre, P.-F., Reychler, G., 2017. Aerosol delivery during invasive mechanical
719 ventilation: a systematic review. *Crit. Care Lond. Engl.* 21, 264.
720 <https://doi.org/10.1186/s13054-017-1844-5>

721 Eichler, H.G., Müller, M., 1998. Drug distribution. The forgotten relative in clinical
722 pharmacokinetics. *Clin. Pharmacokinet.* 34, 95–99.

723 Eisenhut, M., Haberkorn, U., 2006. Molecular position of radiolabels and its impact on
724 functional integrity of proteins. *J. Nucl. Med. Off. Publ. Soc. Nucl. Med.* 47, 1400–
725 1402.

726 Elmquist, W.F., Sawchuk, R.J., 1997. Application of microdialysis in pharmacokinetic
727 studies. *Pharm. Res.* 14, 267–288.

728 European Medicines Agency Committee for Medicinal Products for Human Use, n.d.
729 Guideline on the requirements for clinical documentation for orally inhaled products
730 (OIP) including the requirements for demonstration of therapeutic equivalence
731 between two inhaled products for use in the treatment of asthma and chronic

732 obstructive pulmonary disease (COPD) in adults and for use in the treatment of
733 asthma in children and adolescents.
734 [www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/W](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003504.pdf)
735 [C500003504.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003504.pdf).

736 Fok, T.F., al-Essa, M., Kirpalani, H., Monkman, S., Bowen, B., Coates, G., Dolovich, M.,
737 1999. Estimation of pulmonary deposition of aerosol using gamma scintigraphy. *J.*
738 *Aerosol Med. Off. J. Int. Soc. Aerosols Med.* 12, 9–15.

739 Forbes, B., O’Lone, R., Allen, P.P., Cahn, A., Clarke, C., Collinge, M., Dailey, L.A.,
740 Donnelly, L.E., Dybowski, J., Hassall, D., Hildebrand, D., Jones, R., Kilgour, J.,
741 Klapwijk, J., Maier, C.C., McGovern, T., Nikula, K., Parry, J.D., Reed, M.D.,
742 Robinson, I., Tomlinson, L., Wolfreys, A., 2014. Challenges for inhaled drug
743 discovery and development: Induced alveolar macrophage responses. *Adv. Drug*
744 *Deliv. Rev.* 71, 15–33.

745 Foster, W.M., Walters, D.M., Longphre, M., Macri, K., Miller, L.M., 2001. Methodology for
746 the measurement of mucociliary function in the mouse by scintigraphy. *J. Appl.*
747 *Physiol. Bethesda Md* 1985 90, 1111–1117.

748 Gagnadoux, F., Hureaux, J., Vecellio, L., Urban, T., Le Pape, A., Valo, I., Montharu, J.,
749 Leblond, V., Boisdron-Celle, M., Lerondel, S., Majoral, C., Diot, P., Racineux, J.L.,
750 Lemarie, E., 2008. Aerosolized chemotherapy. *J. Aerosol Med. Pulm. Drug Deliv.* 21,
751 61–70.

752 Gagnadoux, F., Le Pape, A., Urban, T., Montharu, J., Vecellio, L., Dubus, J.-C., Leblond, V.,
753 Diot, P., Grimbert, D., Racineux, J.-L., Lemarié, E., 2005. Safety of pulmonary
754 administration of gemcitabine in rats. *J. Aerosol Med. Off. J. Int. Soc. Aerosols Med.*
755 18, 198–206.

756 Gagnadoux, F., Leblond, V., Vecellio, L., Hureaux, J., Le Pape, A., Boisdron-Celle, M.,
757 Montharu, J., Majoral, C., Fournier, J., Urban, T., Diot, P., Racineux, J.-L., Lemarié,
758 E., 2006. Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for
759 preclinical safety assessment in baboons. *Cancer Chemother. Pharmacol.* 58, 237–
760 244. <https://doi.org/10.1007/s00280-005-0146-9>

761 Gagnadoux, F., Pape, A.L., Lemarié, E., Lerondel, S., Valo, I., Leblond, V., Racineux, J.-L.,
762 Urban, T., 2005. Aerosol delivery of chemotherapy in an orthotopic model of lung
763 cancer. *Eur. Respir. J.* 26, 657–661.

764 Goldenberg, D.M., DeLand, F., Kim, E., Bennett, S., Primus, F.J., van Nagell, J.R., Estes, N.,
765 DeSimone, P., Rayburn, P., 1978. Use of radiolabeled antibodies to carcinoembryonic
766 antigen for the detection and localization of diverse cancers by external
767 photoscanning. *N. Engl. J. Med.* 298, 1384–1386.

768 Guillemainault, L., Azzopardi, N., Arnoult, C., Sobilo, J., Hervé, V., Montharu, J., Guillon, A.,
769 Andres, C., Herault, O., Le Pape, A., Diot, P., Le Marié, E., Paintaud, G., Gouilleux-
770 Gruart, V., Heuzé-Vourc’h, N., 2014. Fate of inhaled monoclonal antibodies after
771 deposition of aerosolized particles in the respiratory system. *J. Control. Release Off.*
772 *J. Control. Release Soc.*

773 Guillon, A., Chevaleyre, C., Barc, C., Berri, M., Adriaensen, H., Lecompte, F., Villemagne,
774 T., Pezant, J., Delaunay, R., Moënné-Loccoz, J., Berthon, P., Bähr, A., Wolf, E.,
775 Klymiuk, N., Attucci, S., Ramphal, R., Sarradin, P., Buzoni-Gatel, D., Si-Tahar, M.,
776 Caballero, I., 2015a. Computed Tomography (CT) Scanning Facilitates Early
777 Identification of Neonatal Cystic Fibrosis Piglets. *PloS One* 10, e0143459.
778 <https://doi.org/10.1371/journal.pone.0143459>

779 Guillon, A., Jouan, Y., Brea, D., Gueugnon, F., Dalloneau, E., Baranek, T., Henry, C.,
780 Morello, E., Renaud, J.-C., Pichavant, M., Gosset, P., Courty, Y., Diot, P., Si-Tahar,

781 M., 2015b. Neutrophil proteases alter the interleukin-22-receptor-dependent lung
782 antimicrobial defence. *Eur. Respir. J.* 46, 771–782.

783 Guillon, A., Mercier, E., Lanotte, P., Haguenoer, E., Barc, C., Sarradin, P., Heuze-Vourc’h,
784 N., Si-Tahar, M., Diot, P., Vecellio, L., 2014. Aerosol Route to Administer
785 Teicoplanin in Mechanical Ventilation: in Vitro Study, Lung Deposition and
786 Pharmacokinetic Analyses in Pigs. *J. Aerosol Med. Pulm. Drug Deliv.*

787 Guillon, A., Mercier, E., Lanotte, P., Haguenoer, E., Darrouzain, F., Barc, C., Sarradin, P.,
788 Si-Tahar, M., Heuzé-Vourc’h, N., Diot, P., Vecellio, L., 2015c. Aerosol Route to
789 Administer Teicoplanin in Mechanical Ventilation: In Vitro Study, Lung Deposition
790 and Pharmacokinetic Analyses in Pigs. *J. Aerosol Med. Pulm. Drug Deliv.* 28, 290–
791 298. <https://doi.org/10.1089/jamp.2014.1164>

792 Guillon, A., Montharu, J., Vecellio, L., Schubnel, V., Roseau, G., Guillemain, J., Diot, P., de
793 Monte, M., 2012. Pulmonary delivery of dry powders to rats: Tolerability limits of an
794 intra-tracheal administration model. *Int. J. Pharm.* 434, 481–487.
795 <https://doi.org/10.1016/j.ijpharm.2012.05.013>

796 Guillon, A., Vecellio, L., de Monte, M., 2016. Pulmonary Delivery of Dry Powders During
797 Invasive Mechanical Ventilation: Innovations Are Required. *J. Aerosol Med. Pulm.*
798 *Drug Deliv.* 29, 215–216. <https://doi.org/10.1089/jamp.2015.1248>

799 Hamacher, J., Arras, M., Bootz, F., Weiss, M., Schramm, R., Moehrlen, U., 2008.
800 Microscopic wire guide-based orotracheal mouse intubation: description, evaluation
801 and comparison with transillumination. *Lab. Anim.* 42, 222–230.
802 <https://doi.org/10.1258/la.2007.006068>

803 Heidl, S., Ellinger, I., Niederberger, V., Walzl, E.E., Fuchs, R., 2016. Localization of the
804 human neonatal Fc receptor (FcRn) in human nasal epithelium. *Protoplasma* 253,
805 1557–1564. <https://doi.org/10.1007/s00709-015-0918-y>

806 Hervé, V., Rabbe, N., Guillemain, L., Paul, F., Schlick, L., Azzopardi, N., Duruisseaux,
807 M., Fouquenot, D., Montharu, J., Redini, F., Paintaud, G., Lemarié, E., Cadranet, J.,
808 Wislez, M., Heuzé-Vourc’h, N., 2014. VEGF neutralizing aerosol therapy in primary
809 pulmonary adenocarcinoma with K-ras activating-mutations. *mAbs* 6, 1638–1648.
810 <https://doi.org/10.4161/mabs.34454>

811 Hofemeier, P., Koshiyama, K., Wada, S., Sznitman, J., 2017. One (sub-)acinus for all: Fate of
812 inhaled aerosols in heterogeneous pulmonary acinar structures. *Eur. J. Pharm. Sci.*
813 *Off. J. Eur. Fed. Pharm. Sci.* <https://doi.org/10.1016/j.ejps.2017.09.033>

814 Hubbard, R.C., Casolaro, M.A., Mitchell, M., Sellers, S.E., Arabia, F., Matthay, M.A.,
815 Crystal, R.G., 1989. Fate of aerosolized recombinant DNA-produced alpha 1-
816 antitrypsin: use of the epithelial surface of the lower respiratory tract to administer
817 proteins of therapeutic importance. *Proc. Natl. Acad. Sci. U. S. A.* 86, 680–684.

818 Huh, D., Matthews, B.D., Mammoto, A., Montoya-Zavala, M., Hsin, H.Y., Ingber, D.E.,
819 2010. Reconstituting organ-level lung functions on a chip. *Science* 328, 1662–1668.
820 <https://doi.org/10.1126/science.1188302>

821 Iizuka, H., Sasaki, K., Odagiri, N., Obo, M., Imaizumi, M., Atai, H., 2010. Measurement of
822 respiratory function using whole-body plethysmography in unanesthetized and
823 unrestrained nonhuman primates. *J. Toxicol. Sci.* 35, 863–870.

824 Jacobson, G.A., Raidal, S., Robson, K., Narkowicz, C.K., Nichols, D.S., Walters, E.H., 2017.
825 Bronchopulmonary pharmacokinetics of (R)-salbutamol and (S)-salbutamol
826 enantiomers in pulmonary epithelial lining fluid and lung tissue of horses. *Br. J. Clin.*
827 *Pharmacol.*

828 Jadhav, S.B., Khaowroongrueng, V., Fueth, M., Otteneder, M.B., Richter, W., Derendorf, H.,
829 2017. Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by
830 Large Pore Microdialysis. *J. Pharm. Sci.*

831 Kamath, A.V., 2016. Translational pharmacokinetics and pharmacodynamics of monoclonal
832 antibodies. *Drug Discov. Today Technol.* 21–22, 75–83.
833 <https://doi.org/10.1016/j.ddtec.2016.09.004>

834 Kawajiri, T., Nagata, N., Morimoto, Y., Ishimatsu, S., Hori, H., Tanaka, I., Yatera, K.,
835 Yoshii, C., Kido, M., 2004. Pathology and mechanism of lung toxicity following
836 inhalation of hair spray in rats. *Inhal. Toxicol.* 16, 147–153.

837 Kipnis, E., 2005. Using urea as an endogenous marker of bronchoalveolar lavage dilution.
838 *Crit. Care Med.* 33, 2153; author reply 2153–2154.

839 Lakatos, H.F., Burgess, H.A., Thatcher, T.H., Redonnet, M.R., Hernady, E., Williams, J.P.,
840 Sime, P.J., 2006. Oropharyngeal aspiration of a silica suspension produces a superior
841 model of silicosis in the mouse when compared to intratracheal instillation. *Exp. Lung*
842 *Res.* 32, 181–199.

843 Lamberts, L.E., Williams, S.P., Terwisscha van Scheltinga, A.G.T., Lub-de Hooge, M.N.,
844 Schröder, C.P., Gietema, J.A., Brouwers, A.H., de Vries, E.G.E., 2015. Antibody
845 positron emission tomography imaging in anticancer drug development. *J. Clin.*
846 *Oncol. Off. J. Am. Soc. Clin. Oncol.* 33, 1491–1504.

847 Larios Mora, A., Detalle, L., Van Geelen, A., Davis, M.S., Stohr, T., Gallup, J.M.,
848 Ackermann, M.R., 2015. Kinetics of Respiratory Syncytial Virus (RSV) Memphis
849 Strain 37 (M37) Infection in the Respiratory Tract of Newborn Lambs as an RSV
850 Infection Model for Human Infants. *PloS One* 10, e0143580.

851 Lewis, D.J., Williams, T.C., Beck, S.L., 2014. Foamy macrophage responses in the rat lung
852 following exposure to inhaled pharmaceuticals: a simple, pragmatic approach for
853 inhaled drug development. *J. Appl. Toxicol. JAT* 34, 319–331.
854 <https://doi.org/10.1002/jat.2950>

855 Lombry, C., Edwards, D.A., Pr at, V., Vanbever, R., 2004. Alveolar macrophages are a
856 primary barrier to pulmonary absorption of macromolecules. *Am. J. Physiol. Lung*
857 *Cell. Mol. Physiol.* 286, L1002–1008. <https://doi.org/10.1152/ajplung.00260.2003>

858 Machac, J., Krynyckiy, B., Kim, C., 2002. Peptide and antibody imaging in lung cancer.
859 *Semin. Nucl. Med.* 32, 276–292.

860 Maillet, A., Guilleminault, L., Lemari , E., Lerondel, S., Azzopardi, N., Montharu, J., Congy-
861 Jolivet, N., Reverdiau, P., Legrain, B., Parent, C., Douvin, D.-H., Hureaux, J., Courty,
862 Y., De Monte, M., Diot, P., Paintaud, G., Le Pape, A., Watier, H., Heuz -Vourc’h, N.,
863 2011. The airways, a novel route for delivering monoclonal antibodies to treat lung
864 tumors. *Pharm. Res.* 28, 2147–2156. <https://doi.org/10.1007/s11095-011-0442-5>

865 Mankikian, J., Ehrmann, S., Guilleminault, L., Le Fol, T., Barc, C., Ferrandi re, M., Boulain,
866 T., Dequin, P.F., Guillon, A., 2014. An evaluation of a new single-use flexible
867 bronchoscope with a large suction channel: reliability of bronchoalveolar lavage in
868 ventilated piglets and initial clinical experience. *Anaesthesia* 69, 701–706.
869 <https://doi.org/10.1111/anae.12641>

870 March, T.H., Cossey, P.Y., Esparza, D.C., Dix, K.J., McDonald, J.D., Bowen, L.E., 2004.
871 Inhalation administration of all-trans-retinoic acid for treatment of elastase-induced
872 pulmonary emphysema in Fischer 344 rats. *Exp. Lung Res.* 30, 383–404.

873 March, T.H., Green, F.H., Hahn, F.F., Nikula, K.J., 2000. Animal models of emphysema and
874 their relevance to studies of particle-induced disease. *Inhal. Toxicol.* 12 Suppl 4, 155–
875 187.

876 Marchand, S., Bouchene, S., de Monte, M., Guilleminault, L., Montharu, J., Cabrera, M.,
877 Gr goire, N., Gobin, P., Diot, P., Couet, W., Vecellio, L., 2015. Pharmacokinetics of
878 Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon
879 Monkeys. *Pharm. Res.* 32, 3403–3414.

880 Matsukawa, Y., Lee, V.H., Crandall, E.D., Kim, K.J., 1997. Size-dependent dextran transport
881 across rat alveolar epithelial cell monolayers. *J. Pharm. Sci.* 86, 305–309.

882 McClellan, R.O., Henderson, R., 1989. Concepts in inhalation toxicology, Hemisphere
883 Publishing, New York. ed.

884 McElroy, M.C., Kirton, C., Gliddon, D., Wolff, R.K., 2013. Inhaled biopharmaceutical drug
885 development: nonclinical considerations and case studies. *Inhal. Toxicol.* 25, 219–
886 232. <https://doi.org/10.3109/08958378.2013.769037>

887 Mercier, E., Darrouzain, F., Montharu, J., Guillon, A., Diot, P., Paintaud, G., Vecellio, L.,
888 2014. Lung and serum teicoplanin concentration after aerosol and intravenous
889 administration in a rat model. *J. Aerosol Med. Pulm. Drug Deliv.* 27, 306–312.

890 Montharu, J., Le Guellec, S., Kittel, B., Rabemampianina, Y., Guillemain, J., Gauthier, F.,
891 Diot, P., de Monte, M., 2010. Evaluation of lung tolerance of ethanol, propylene
892 glycol, and sorbitan monooleate as solvents in medical aerosols. *J. Aerosol Med.*
893 *Pulm. Drug Deliv.* 23, 41–46. <https://doi.org/10.1089/jamp.2008.0740>

894 Morgan, D.L., Flake, G.P., Kirby, P.J., Palmer, S.M., 2008. Respiratory toxicity of diacetyl in
895 C57BL/6 mice. *Toxicol. Sci. Off. J. Soc. Toxicol.* 103, 169–180.

896 Nag, K., Hillier, A., Parsons, K., Garcia, M.F., 2007. Interactions of serum with lung
897 surfactant extract in the bronchiolar and alveolar airway models. *Respir. Physiol.*
898 *Neurobiol.* 157, 411–424. <https://doi.org/10.1016/j.resp.2007.02.001>

899 Nagengast, W.B., Hooge, M.N.L., van Straten, E.M.E., Kruijff, S., Brouwers, A.H., den
900 Dunnen, W.F.A., de Jong, J.R., Hollema, H., Dierckx, R.A., Mulder, N.H., de Vries,
901 E.G.E., Hoekstra, H.J., Hospers, G.A.P., 2011. VEGF-SPECT with ¹¹¹In-bevacizumab
902 in stage III/IV melanoma patients. *Eur. J. Cancer Oxf. Engl.* 1990 47, 1595–1602.
903 <https://doi.org/10.1016/j.ejca.2011.02.009>

904 Nair, A.B., Jacob, S., 2016. A simple practice guide for dose conversion between animals and
905 human. *J. Basic Clin. Pharm.* 7, 27–31. <https://doi.org/10.4103/0976-0105.177703>

906 Newman, S., Bennett, W.D., Biddiscombe, M., Devadason, S.G., Dolovich, M.B., Fleming,
907 J., Haeussermann, S., Kietzig, C., Kuehl, P.J., Laube, B.L., Sommerer, K., Taylor, G.,
908 Usmani, O.S., Zeman, K.L., 2012. Standardization of techniques for using planar (2D)
909 imaging for aerosol deposition assessment of orally inhaled products. *J. Aerosol Med.*
910 *Pulm. Drug Deliv.* 25 Suppl 1, S10-28.

911 Owen, K., 2013. Regulatory toxicology considerations for the development of inhaled
912 pharmaceuticals. *Drug Chem. Toxicol.* 36, 109–118.

913 Paintaud, G., 2009. [Pharmacokinetics (PK) of mAbs]. *Médecine Sci. MS* 25, 1057–1062.

914 Patel, A., Woods, A., Riffo-Vasquez, Y., Babin-Morgan, A., Jones, M.-C., Jones, S.,
915 Sunassee, K., Clark, S., T M de Rosales, R., Page, C., Spina, D., Forbes, B., Dailey,
916 L.A., 2016. Lung inflammation does not affect the clearance kinetics of lipid
917 nanocapsules following pulmonary administration. *J. Control. Release Off. J. Control.*
918 *Release Soc.* 235, 24–33.

919 Paul, G., Somers, G., Moore, S., Goodway, R., 2012. The Capsule Based Aerosol Generator
920 – Conserving Test Article in Small Scale Inhalation Exposures. *Respir. Drug Deliv.* 2,
921 525–530.

922 Pauluhn, J., 2014. Repeated inhalation exposure of rats to an anionic high molecular weight
923 polymer aerosol: application of prediction models to better understand pulmonary
924 effects and modes of action. *Exp. Toxicol. Pathol. Off. J. Ges. Für Toxikol. Pathol.*
925 66, 243–256.

926 Pauluhn, J., 2006. Acute nose-only exposure of rats to phosgene. Part II. Concentration x
927 time dependence of changes in bronchoalveolar lavage during a follow-up period of 3
928 months. *Inhal. Toxicol.* 18, 595–607.

929 Pauluhn, J., Mohr, U., 2000. Inhalation studies in laboratory animals--current concepts and
930 alternatives. *Toxicol. Pathol.* 28, 734–753.

931 Phalen, R.F., Oldham, M.J., 1983. Tracheobronchial airway structure as revealed by casting
932 techniques. *Am. Rev. Respir. Dis.* 128, S1-4.

933 Phalen, R.F., Oldham, M.J., Wolff, R.K., 2008. The relevance of animal models for aerosol
934 studies. *J. Aerosol Med. Pulm. Drug Deliv.* 21, 113–124.

935 Phillips, J.E., 2017. Inhaled efficacious dose translation from rodent to human: A
936 retrospective analysis of clinical standards for respiratory diseases. *Pharmacol. Ther.*

937 Presant, C.A., Wolf, W., Waluch, V., Wiseman, C., Kennedy, P., Blayney, D., Brechner,
938 R.R., 1994. Association of intratumoral pharmacokinetics of fluorouracil with clinical
939 response. *Lancet Lond. Engl.* 343, 1184–1187.

940 Rao, G.V.S., Tinkle, S., Weissman, D.N., Antonini, J.M., Kashon, M.L., Salmen, R., Battelli,
941 L.A., Willard, P.A., Hoover, M.D., Hubbs, A.F., 2003. Efficacy of a technique for
942 exposing the mouse lung to particles aspirated from the pharynx. *J. Toxicol. Environ.*
943 *Health A* 66, 1441–1452.

944 Reichert, J.M., 2016. Antibodies to watch in 2016. *mAbs* 8, 197–204.

945 Réminiac, F., Vecellio, L., Loughlin, R.M., Le Pennec, D., Cabrera, M., Vourc'h, N.H., Fink,
946 J.B., Ehrmann, S., 2017. Nasal high flow nebulization in infants and toddlers: An in
947 vitro and in vivo scintigraphic study. *Pediatr. Pulmonol.* 52, 337–344.
948 <https://doi.org/10.1002/ppul.23509>

949 Respaud, R., Marchand, D., Pelat, T., Tchou-Wong, K.-M., Roy, C.J., Parent, C., Cabrera,
950 M., Guillemain, J., Mac Loughlin, R., Levacher, E., Fontayne, A., Douziech-Eyrolles,
951 L., Junqua-Moulet, A., Guilleminault, L., Thullier, P., Guillot-Combe, E., Vecellio,
952 L., Heuzé-Vourc'h, N., 2016. Development of a drug delivery system for efficient
953 alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary
954 intoxication to ricin. *J. Control. Release Off. J. Control. Release Soc.* 234, 21–32.

955 Respaud, R., Vecellio, L., Diot, P., Heuzé-Vourc'h, N., 2015. Nebulization as a delivery
956 method for mAbs in respiratory diseases. *Expert Opin. Drug Deliv.* 12, 1027–1039.

957 Rivera, B., Miller, S., Brown, E., Price, R., 2005. A novel method for endotracheal intubation
958 of mice and rats used in imaging studies. *Contemp. Top. Lab. Anim. Sci. Am. Assoc.*
959 *Lab. Anim. Sci.* 44, 52–55.

960 Robichaud, A., Fereydoonzad, L., Schuessler, T.F., 2015. Delivered dose estimate to
961 standardize airway hyperresponsiveness assessment in mice. *Am. J. Physiol. Lung*
962 *Cell. Mol. Physiol.* 308, L837-846.

963 Rogers, C.S., Abraham, W.M., Brogden, K.A., Engelhardt, J.F., Fisher, J.T., McCray, P.B.,
964 McLennan, G., Meyerholz, D.K., Namati, E., Ostedgaard, L.S., Prather, R.S., Sabater,
965 J.R., Stoltz, D.A., Zabner, J., Welsh, M.J., 2008. The porcine lung as a potential
966 model for cystic fibrosis. *Am. J. Physiol. - Lung Cell. Mol. Physiol.* 295, L240–L263.

967 Röhm, M., Carle, S., Maigler, F., Flamm, J., Kramer, V., Mavoungou, C., Schmid, O.,
968 Schindowski, K., 2017. A comprehensive screening platform for aerosolizable protein
969 formulations for intranasal and pulmonary drug delivery. *Int. J. Pharm.* 532, 537–546.
970 <https://doi.org/10.1016/j.ijpharm.2017.09.027>

971 Roopenian, D.C., Akilesh, S., 2007. FcRn: the neonatal Fc receptor comes of age. *Nat. Rev.*
972 *Immunol.* 7, 715–725. <https://doi.org/10.1038/nri2155>

973 Rouby, J.-J., Bouhemad, B., Monsel, A., Brisson, H., Arbelot, C., Lu, Q., Nebulized
974 Antibiotics Study Group, 2012. Aerosolized antibiotics for ventilator-associated
975 pneumonia: lessons from experimental studies. *Anesthesiology* 117, 1364–1380.

976 Saffiotti, U., Cefis, F., Kolb, L.H., 1968. A method for the experimental induction of
977 bronchogenic carcinoma. *Cancer Res.* 28, 104–124.

978 Salem, H., Katz, S.A., 2005. *Inhalation Toxicology*, Second Edition. CRC Press.

- 979 Sauerborn, M., Brinks, V., Jiskoot, W., Schellekens, H., 2010. Immunological mechanism
980 underlying the immune response to recombinant human protein therapeutics. *Trends*
981 *Pharmacol. Sci.* 31, 53–59.
- 982 Schanker, L.S., Hemberger, J.A., 1983. Relation between molecular weight and pulmonary
983 absorption rate of lipid-insoluble compounds in neonatal and adult rats. *Biochem.*
984 *Pharmacol.* 32, 2599–2601.
- 985 Schanker, L.S., Mitchell, E.W., Brown, R.A., Jr, 1986. Species comparison of drug
986 absorption from the lung after aerosol inhalation or intratracheal injection. *Drug*
987 *Metab. Dispos. Biol. Fate Chem.* 14, 79–88.
- 988 Schellekens, H., 2002. Bioequivalence and the immunogenicity of biopharmaceuticals. *Nat.*
989 *Rev. Drug Discov.* 1, 457–462.
- 990 Schlesinger, R.B., 1985. Comparative deposition of inhaled aerosols in experimental animals
991 and humans: a review. *J. Toxicol. Environ. Health* 15, 197–214.
- 992 Schreider, J.P., Raabe, O.G., 1981. Anatomy of the nasal-pharyngeal airway of experimental
993 animals. *Anat. Rec.* 200, 195–205.
- 994 Sellers, S., Horodnik, W., House, A., Wylie, J., Mauser, P., Garber, N., Pu, Y.E., Berry, J.,
995 Donovan, B., 2015. The in vitro and in vivo investigation of inhaled migraine
996 therapies using a novel aerosol delivery system consisting of an air pressurized
997 capsule device (APCD) in combination with a pMDI spacer for endotracheal dosing
998 into beagle dogs. *Drug Dev. Ind. Pharm.* 41, 1989–1996.
- 999 Siegwart, B., Gehr, P., Gil, J., Weibel, E.R., 1971. Morphometric estimation of pulmonary
1000 diffusion capacity. IV. The normal dog lung. *Respir. Physiol.* 13, 141–159.
- 1001 Smith, A., Manoli, H., Jaw, S., Frutoz, K., Epstein, A.L., Khawli, L.A., Theil, F.-P., 2016.
1002 Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of
1003 Therapeutic Proteins. *J. Immunol. Res.* 2016, 2342187.
- 1004 Spoelstra, E.N., Ince, C., Koeman, A., Emons, V.M., Brouwer, L.A., van Luyn, M.J.A.,
1005 Westerink, B.H.C., Remie, R., 2007. A novel and simple method for endotracheal
1006 intubation of mice. *Lab. Anim.* 41, 128–135.
- 1007 Tam, S.H., McCarthy, S.G., Brosnan, K., Goldberg, K.M., Scallon, B.J., 2013. Correlations
1008 between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice
1009 reveal a rodent model with predictive capabilities. *mAbs* 5, 397–405.
1010 <https://doi.org/10.4161/mabs.23836>
- 1011 Thompson, R.B., Finlay, W.H., 2012. Using MRI to measure aerosol deposition. *J. Aerosol*
1012 *Med. Pulm. Drug Deliv.* 25, 55–62.
- 1013 Todo, H., Iida, K., Okamoto, H., Danjo, K., 2003. Improvement of insulin absorption from
1014 intratracheally administered dry powder prepared by supercritical carbon dioxide
1015 process. *J. Pharm. Sci.* 92, 2475–2486. <https://doi.org/10.1002/jps.10497>
- 1016 Tronde, A., Baran, G., Eirefelt, S., Lennernäs, H., Bengtsson, U.H., 2002. Miniaturized
1017 nebulization catheters: a new approach for delivery of defined aerosol doses to the rat
1018 lung. *J. Aerosol Med. Off. J. Int. Soc. Aerosols Med.* 15, 283–296.
- 1019 Tyler, W.S., 1983. Comparative subgross anatomy of lungs. Pleuras, interlobular septa, and
1020 distal airways. *Am. Rev. Respir. Dis.* 128, S32–36.
- 1021 Wahl, R.L., Parker, C.W., Philpott, G.W., 1983. Improved radioimaging and tumor
1022 localization with monoclonal F(ab')₂. *J. Nucl. Med. Off. Publ. Soc. Nucl. Med.* 24,
1023 316–325.
- 1024 Wang, H., Sebríe, C., Ruaud, J.-P., Guillot, G., Bouazizi-Verdier, K., Willoquet, G., Maître,
1025 X., Darrasse, L., de Rochefort, L., 2016. Aerosol deposition in the lungs of
1026 spontaneously breathing rats using Gd-DOTA-based contrast agents and ultra-short
1027 echo time MRI at 1.5 Tesla. *Magn. Reson. Med.* 75, 594–605.

1028 Wang, J., Iyer, S., Fielder, P.J., Davis, J.D., Deng, R., 2016. Projecting human
1029 pharmacokinetics of monoclonal antibodies from nonclinical data: comparative
1030 evaluation of prediction approaches in early drug development. *Biopharm. Drug*
1031 *Dispos.* 37, 51–65. <https://doi.org/10.1002/bdd.1952>

1032 Warheit, D.B., 1989. Interspecies comparisons of lung responses to inhaled particles and
1033 gases. *Crit. Rev. Toxicol.* 20, 1–29. <https://doi.org/10.3109/10408448909037474>

1034 Weinstein, E.A., Liu, L., Ordonez, A.A., Wang, H., Hooker, J.M., Tonge, P.J., Jain, S.K.,
1035 2012. Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide
1036 pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-
1037 infected mice. *Antimicrob. Agents Chemother.* 56, 6284–6290.

1038 Wolff, R.K., 2015. Toxicology Studies for Inhaled and Nasal Delivery. *Mol. Pharm.* 12,
1039 2688–2696.

1040 Woods, A., Patel, A., Spina, D., Riffo-Vasquez, Y., Babin-Morgan, A., de Rosales, R.T.M.,
1041 Sunassee, K., Clark, S., Collins, H., Bruce, K., Dailey, L.A., Forbes, B., 2015. In vivo
1042 biocompatibility, clearance, and biodistribution of albumin vehicles for pulmonary
1043 drug delivery. *J. Control. Release Off. J. Control. Release Soc.* 210, 1–9.

1044 Wu, Y., Kotzer, C.J., Makrogiannis, S., Logan, G.A., Haley, H., Barnette, M.S., Sarkar, S.K.,
1045 2011. A noninvasive [99mTc]DTPA SPECT/CT imaging methodology as a measure
1046 of lung permeability in a guinea pig model of COPD. *Mol. Imaging Biol. MIB Off.*
1047 *Publ. Acad. Mol. Imaging* 13, 923–929.

1048 Yamamoto, T., Kobayashi, Y., Shikano, S., Takeyama, M., Asako, M., Tomoda, K., 2017.
1049 Flow Visualization for Nasal Cavity Flow in Aerosol Exhalation Through Nose
1050 Treatment, in: *The 16th International Conference on Biomedical Engineering, IFMBE*
1051 *Proceedings*. Springer, Singapore, pp. 53–57. [https://doi.org/10.1007/978-981-10-](https://doi.org/10.1007/978-981-10-4220-1_11)
1052 [4220-1_11](https://doi.org/10.1007/978-981-10-4220-1_11)

1053 Yao, Y.-F., Yang, Z., Li, Z.-F., Gu, J., 2007. Immunoscintigraphy of local recurrent rectal
1054 cancer with 99mTc-labeled anti-CEA monoclonal antibody CL58. *World J.*
1055 *Gastroenterol.* 13, 1841–1846.

1056 Yeh, H.C., Brinker, R.M., Harkema, J.R., Muggenburg, B.A., 1997. A comparative analysis
1057 of primate nasal airways using magnetic resonance imaging and nasal casts. *J.*
1058 *Aerosol Med. Off. J. Int. Soc. Aerosols Med.* 10, 319–329.

1059 Zeitlinger, M., Müller, M., Joukhadar, C., 2005. Lung microdialysis--a powerful tool for the
1060 determination of exogenous and endogenous compounds in the lower respiratory tract
1061 (mini-review). *AAPS J.* 7, E600-608.
1062

1063 **Acknowledgments:**

1064 This work was supported by a public grant overseen by the French National Research Agency (ANR) as part of
1065 the “Investissements d'Avenir” program (reference: ANR-10-LABX -53-01). It was also supported by two
1066 grants provided by Région Centre (MicroPulm and Flukiller).

1067

1068 **Figure legends**

1069

1070 **Figure 1.** Integrated scheme of advantages and limitations of animal models used to investigate aerosol drug
1071 delivery in pulmonary research. Anatomical and physiological features were obtained from (Asgharian et al.,
1072 2012; Crapo et al., 1983; Phalen and Oldham, 1983; Siegwart et al., 1971); animal pictures were obtained from
1073 Servier Medical Art.

1074

1075 **Figure 2. Inter-species respiratory physiological differences.** Respiratory rates (A) and tidal volumes (B) are
1076 expressed according to the body weight in several animal species (Asgharian et al., 2012; Bassett et al., 2014;
1077 Cryan et al., 2007).

1078

1079 **Supplementary figure 1. Assessment of the lung distribution of a nebulized drug in a conscious non-**
1080 **human primate.** An aerosol is delivered through a face mask connected to an aerosol generator in a
1081 spontaneously breathing non-human primate (A). The lung deposition of the drug traced with ^{99m}Tc -DTPA is
1082 evaluated with a 2D-scintigraphic imaging sequence. The Regions of Interest (ROI) are: 1.lung, 2. ENT, 3.
1083 stomach and 4. bladder (B).

1084

1085 **Supplementary figure 2. Intra-tracheal administration of an aerosol of a liquid solution containing a**
1086 **fluorescent dye, in mice.** Briefly, anesthetized mouse was suspended by the teeth positioned on a platform
1087 slanted at a 45° angle and a small-animal otoscope used to visualize the vocal cords and facilitate insertion of
1088 the a MicroSprayer® Aerosolizer (connected to a high-pressure syringe) into the trachea (A). After delivering
1089 $50\mu\text{L}$ of dye solution, kinetic of dye deposition into the lungs was followed up by near-infrared imaging (B).

1090

1091 **Supplementary figure 3. Important anatomy similarities exist between porcine and human lungs.** The
1092 comparable size and anatomy of pig and human lungs make this model particularly beneficial for translational
1093 research. The lungs of pigs are lobulated broadly similar to the human lung: the left lung is composed of a
1094 cranial lobe and a caudal lobe, the right lung is composed of four lobes (cranial, middle, caudal, and accessory –
1095 not observed in human). (A) Images of the porcine tracheo-bronchial tree obtained by flexible video-
1096 bronchoscopy (here, the carena is observed). (B) Ex-vivo ventilated lungs of a 20 kg large-White pig.

1097

1098 **Supplementary figure 4. Methods of lung microdialysis.** A probe with a semi-permeable membrane is
1099 implanted within the lungs under direct vision during thoracic surgery. The probe is continuously perfused with
1100 a physiological solution (perfusate) at a very slow flow rate (usually 1 to $10\mu\text{L}/\text{min}$) and the dialysate is
1101 collected at timed intervals. It contains substances/drugs from the interstitial space fluid that diffused passively
1102 through the membrane pores, along their concentration gradient.

1103

1104

1105